Literature DB >> 18419501

Numbers needed to treat with posaconazole prophylaxis to prevent invasive fungal infection and death.

Oliver A Cornely, Andrew J Ullmann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18419501     DOI： 10.1086/587177

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  8 in total

1.  Canadian clinical practice guidelines for invasive candidiasis in adults.

Authors:  Eric J Bow; Gerald Evans; Jeff Fuller; Michel Laverdière; Coleman Rotstein; Robert Rennie; Stephen D Shafran; Don Sheppard; Sylvie Carle; Peter Phillips; Donald C Vinh
Journal:  Can J Infect Dis Med Microbiol       Date:  2010       Impact factor: 2.471

2.  Clinical pharmacodynamics and pharmacokinetics of the antifungal extended-spectrum triazole posaconazole: an overview.

Authors:  Hans-Peter Lipp
Journal:  Br J Clin Pharmacol       Date:  2010-10       Impact factor: 4.335

3.  Pentraxin-3 polymorphisms and invasive mold infections in acute leukemia patients receiving intensive chemotherapy.

Authors:  Anne-Sophie Brunel; Agnieszka Wójtowicz; Frédéric Lamoth; Olivier Spertini; Dionysios Neofytos; Thierry Calandra; Oscar Marchetti; Pierre-Yves Bochud
Journal:  Haematologica       Date:  2018-06-07       Impact factor: 9.941

4.  Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period.

Authors:  Michelle R Ananda-Rajah; Andrew Grigg; Maria T Downey; Ashish Bajel; Tim Spelman; Allen Cheng; Karin T Thursky; Janette Vincent; Monica A Slavin
Journal:  Haematologica       Date:  2011-11-04       Impact factor: 9.941

5.  Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation.

Authors:  John R Wingard; Shelly L Carter; Thomas J Walsh; Joanne Kurtzberg; Trudy N Small; Lindsey R Baden; Iris D Gersten; Adam M Mendizabal; Helen L Leather; Dennis L Confer; Richard T Maziarz; Edward A Stadtmauer; Javier Bolaños-Meade; Janice Brown; John F Dipersio; Michael Boeckh; Kieren A Marr
Journal:  Blood       Date:  2010-09-08       Impact factor: 22.113

6.  Antifungal Prophylaxis in Acute Myeloid Leukemia: New Drugs, New Challenges?: Summary of the EHA Guideline on Antifungal Prophylaxis in Adult Patients With Acute Myeloid Leukemia Treated With Novel-targeted Therapies.

Authors:  Jannik Stemler; Oliver A Cornely
Journal:  Hemasphere       Date:  2022-06-17

7.  Prevalence of invasive fungal disease in hematological patients at a tertiary university hospital in Singapore.

Authors:  Siok-Ying Lee; Chay-Leng Yeo; Winnie H Lee; Andrea L Kwa; Liang-Piu Koh; Li-Yang Hsu
Journal:  BMC Res Notes       Date:  2011-02-28

Review 8.  Antifungal prophylaxis and novel drugs in acute myeloid leukemia: the midostaurin and posaconazole dilemma.

Authors:  Jannik Stemler; Philipp Koehler; Christian Maurer; Carsten Müller; Oliver A Cornely
Journal:  Ann Hematol       Date:  2020-06-08       Impact factor: 3.673
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.